Meet Our Team

Tom Shea is the founding President of Xentria overseeing all aspects of business development, clinical, regulatory, and commercial operations. Tom is also the founding CEO of Meitheal Pharmaceutical, Inc., a generic pharmaceutical company focused on development, manufacture and supply of generic injectable products, which was established in January 2017.

Prior to joining Xentria and Meitheal, Tom was Vice President of Global Alliance Management for Sagent Pharmaceuticals and was responsible for global partnerships, supply chain and product development. Before his work at Sagent, Tom held various roles at APP, now Fresenius Kabi North America, in Commercial Operations and Business Development, focusing on Portfolio Management and National Accounts.

Tom started his pharmaceutical career as a Sales Rep at Fougera, now Sandoz. During his tenure at Fougera, he held positions of increasing responsibilities eventually attaining the position of National Sales Manager. Tom earned an M.B.A. from Notre Dame University and a B.A. in Philosophy from Marquette University.

Victoria is the General Counsel & Corporate Secretary of Xentria overseeing all legal and corporate governance matters. Victoria is also the General Counsel & Corporate Secretary of Meitheal Pharmaceutical, Inc., a generic pharmaceutical company focused on development, manufacture and supply of generic injectable products, which was established in January 2017.

Prior to joining Xentria and Meitheal, Victoria worked for Sagent Pharmaceuticals where she most recently served as Associate General Counsel and Assistant Secretary. Victoria started her legal career in private law practice in Chicago, Illinois. She has experience in acquisitions and dispositions, corporate and security transactions and intellectual property matters, including both domestic and international business transactions, litigation management and regulatory and quality assurance compliance.

Victoria earned her J.D. and LL.M in Intellectual Property from the John Marshall Law School and her B.S. in Operations Management & Information Systems from Northern Illinois University.

Dr Nancy Sacco is Vice President and Head of Clinical Development at Meitheal Specialty Pharma/Xentria with 20+ years Drug Development experience, from bench to product registrations (US and ex-US). Prior to joining Xentria she led Clinical Development and Clinical Operations at AnaptysBio, Global Clinical Operations at Revance, Avexis and Takeda, having overseen clinical trials in aesthetics, neuromuscular diseases, psychiatric disorders, metabolic disease, women’s health, infectious diseases/immunology, oncology, and gene therapy/rare disease.

She was Executive Director of Strategic Operations at Astellas with responsibilities across US, Europe and Japan. She has contributed to the development of DaxibotulinumtoxinA for glabellar lines, cervical dystonia and upper limb spasticity, Zolgensma for SMA, Xtandi for prostatic cancer, Myrbetriq for OAB, as well as Cresemba, Lyrica, Rozerem and Risedronate.

Over her career she has been involved in setting Industry Best Practices through Transcelerate and AVOCA. Nancy received both a MS and PhD from WVU School of Medicine, completed postdoctoral training at Loyola Stritch School of Medicine and a toxicology research fellowship at Argonne National Laboratory.